Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide.
Adequate balance sheet average dividend payer.
Share Price & News
How has Guerbet's share price performed over time and what events caused price changes?
Latest Share Price and Events
7 Day Return
FR Medical Equipment
1 Year Return
FR Medical Equipment
Price Volatility Vs. Market
How volatile is Guerbet's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StIs It Smart To Buy Guerbet SA (EPA:GBT) Before It Goes Ex-Dividend?
1 month ago | Simply Wall StRead This Before Buying Guerbet SA (EPA:GBT) For Its Dividend
1 month ago | Simply Wall StDeclining Stock and Solid Fundamentals: Is The Market Wrong About Guerbet SA (EPA:GBT)?
Is Guerbet undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Price To Earnings Ratio
Price to Earnings Growth Ratio
Price to Book Ratio
How is Guerbet forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings per Share Growth Forecasts
Future Return on Equity
How has Guerbet performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Return on Equity
How is Guerbet's financial position?
Financial Position Analysis
Debt to Equity History and Analysis
What is Guerbet current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Stability and Growth of Payments
Current Payout to Shareholders
Future Payout to Shareholders
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Hale (51yo)
Mr. David Hale has been Chief Executive Officer of Guerbet SA since January 1, 2020. Mr. Hale served as Chief Commercial Officer of Guerbet SA since 2019 until January 1, 2020 and served as its Chief Comme ...
|Chief Pharmaceutical Officer & Deputy CEO||4.25yrs||€236.95k||no data|
|Chief Executive Officer||0.50yr||no data||no data|
|Chief Financial Officer||1.25yrs||no data||no data|
|Vice President of Purchasing & Member of Management Board||no data||no data||no data|
|Vice President of Communications & Image||no data||no data||no data|
|VP of European Operations & Member of Management Board||no data||no data||no data|
|Member of Management Board||no data||no data||no data|
|Chief Information Officer & Member of Management Board||no data||no data||no data|
|Vice President of Human Resources||0.50yr||no data||no data|
|Chief Digital Officer and VP of Contrast Injection Systems R&D||2.83yrs||no data||no data|
|Non-Independent Director||9yrs||€24.00k||no data|
|Independent Director||3.17yrs||€25.50k||no data|
|Honorary Chairman||no data||€18.96k||54.87% €228.0m|
|Independent Chairwoman of the Board||6.83yrs||€124.13k||no data|
|Non-Independent Director||7.17yrs||€27.00k||no data|
|Non-Independent Director||6.17yrs||€26.00k||no data|
|Independent Director||6.17yrs||€37.50k||no data|
|Non-Independent Director||5.17yrs||€23.00k||no data|
|Non-Independent Director||4.17yrs||€24.00k||no data|
|Non-Independent Director||3.17yrs||€22.50k||no data|
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Guerbet SA's company bio, employee growth, exchange listings and data sources
- Name: Guerbet SA
- Ticker: GBT
- Exchange: ENXTPA
- Founded: 1926
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: €415.486m
- Shares outstanding: 12.55m
- Website: https://www.guerbet.com
Number of Employees
- Guerbet SA
- 15, rue des Vanesses
- Zone Paris Nord II
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GUER.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 1992|
|GBT||ENXTPA (Euronext Paris)||Yes||Ordinary Shares||FR||EUR||Jan 1992|
|0ELV||LSE (London Stock Exchange)||Yes||Ordinary Shares||GB||EUR||Jan 1992|
|4G8||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jan 1992|
|GBTP||BATS-CHIXE (BATS 'Chi-X Europe')||Yes||Ordinary Shares||GB||EUR||Jan 1992|
Guerbet SA engages in the research, development, production, and sale of contrast media products, delivery systems, medical devices, and related solutions worldwide. Its products for the CT and Cath Lab examinations include Optiray, a low osmolar contrast medium; Xenetix, a low-osmolar iodinated agent; Telebrix, a high osmolar contrast medium; Conray and MD high osmolar contrast medium products; and high osmolar contrast medium, an ionic low osmolar contrast medium agent. The company’s products for the magnetic resonance imaging (MRI) examinations comprise Dotarem, a non-specific gadolinium-based contrast medium; Artirem products; and Optimark, a contrast medium. In addition, it provides products for interventional imaging, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a classic transarterial chemoembolization mixing and injection system; and Patent Blue V, an injectable medium. Further, the company offers delivery systems and services comprising injectors; consumables for various types of injectors; and Contrast&Care, a patient data management software. The company distributes its products directly, as well as through distributors and license-holders primarily to hospitals, clinics, radiology centers, purchasing pools, and wholesalers. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/09 20:55|
|End of Day Share Price||2020/07/09 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.